Treatment for Muscle Atrophy and for Enhancing Muscle Growth

Summary

Technology Description

 

This technology licensing and collaboration opportunity is for an mRNA based therapeutic that provides for increased hepatic production of follistatin (FS). In vivo experiments demonstrate delivered mRNA accumulates in the liver, which results in an increase of FS in blood serum. Mouse studies demonstrate a subcutaneous injection regimen capable of increasing a subject’s body weight over a month’s time.

 

Features & Benefits

 

  • Hepatic production and secretion of FS protein
  • Compatible with sustained release formulations for in home treatment by a patient

 

Applications

 

  • Treating muscle wasting disorders
  • Enhancing muscle growth

 

Background of Invention

 

Muscle atrophy is a detrimental and often severely debilitating disease state whose etiology lies within a myriad of disease states ranging from AIDS, sepsis, cardiac failure, muscular dystrophies, cancer, and the natural process of aging. The extent to which the atrophy is occurring can be a clear prognostic indicator of patient recovery and survival. Furthermore, the ability to maintain healthy lean muscle mass whether through exercise or other therapeutic interventions is crucial for the preservation of mobility during aging, preventing metabolic disorders, and increasing both quality and longevity of life in patients experiencing disease states that promote active muscle wasting.

 

Status

 

Patent pending

 

Patent Information:
Tech ID:
OSU-16-44
Category(s):
Therapeutics
Contact:
Joe Christison
IP & Licensing Manager
Oregon State University
541-737-9016
joe.christison@oregonstate.edu
Inventors:
Oleh Taratula
Canan Schumann
Olena Taratula
Adam (Wathah) Alani
Keywords:
atrophy
growth
mRNA carrier
mRNA delivery
muscle
Muscular Dystrophy
wasting
© 2018. All Rights Reserved. Powered by Inteum